Disease · MONDO_0021113
Comparisons in its trials62
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 62
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Dapagliflozin 10mg vs Placebo: Improving Clinical Recovery: Hierarchical Composite Outcome Measure Including Death From Any Cause Through Day 30, New/Worsened Organ Dysfunction, Clinical Status at Day 30 and Hospital Discharge Before Day 30 and Alive at Day 30. | 547 of 625 | 532 of 625 | 1,250 | NCT04350593 | Trial comparisons |
| Dapagliflozin 10mg vs Placebo: deaths from any cause | 41 of 625 | 54 of 625 | 1,250 | NCT04350593 | Trial comparisons |
| Dapagliflozin 10mg vs Placebo: serious adverse events | 70 of 613 | 87 of 616 | 1,229 | NCT04350593 | Trial comparisons |
| Tocilizumab vs Placebo: deaths from any cause | 9 of 161 | 4 of 82 | 243 | NCT04356937 | Trial comparisons |
| Tocilizumab vs Placebo: serious adverse events | 19 of 161 | 8 of 82 | 243 | NCT04356937 | Trial comparisons |
| Aviptadil IV in Escalating Doses + Standard of Care vs Placebo + Standard of Care: Number of Participants Achieving a Score of 6-8 on NIAID Ordinal Score Through Day 60 | 76 of 131 | 35 of 65 | 196 | NCT04311697 | Trial comparisons |
| Aviptadil IV in Escalating Doses + Standard of Care vs Placebo + Standard of Care: Resolution of Respiratory Failure (Alive and Free of Respiratory Failure) | 72 of 131 | 33 of 65 | 196 | NCT04311697 | Trial comparisons |
| Aviptadil IV in Escalating Doses + Standard of Care vs Placebo + Standard of Care: Number of Participants Alive at Day 60 | 85 of 131 | 35 of 65 | 196 | NCT04311697 | Trial comparisons |
| Aviptadil IV in Escalating Doses + Standard of Care vs Placebo + Standard of Care: deaths from any cause | 46 of 131 | 30 of 65 | 196 | NCT04311697 | Trial comparisons |
| Aviptadil IV in Escalating Doses + Standard of Care vs Placebo + Standard of Care: serious adverse events | 58 of 131 | 32 of 65 | 196 | NCT04311697 | Trial comparisons |
| Lucinactant vs Sham Air: serious adverse events | 20 of 84 | 14 of 81 | 165 | NCT00578734 | Trial comparisons |
| Open Label Losartan vs External Controls: Number of Participants With Increase of Supplemental Oxygen Needs From Baseline. | 4 of 30 | 12 of 46 | 76 | NCT04335123 | Trial comparisons |
Open Label Losartan vs External Controls: Number of Participants With Medications With Possible Antiviral Activity (Hydroxychloroquine, Lopinavir/Ritonavir, Ribavirin or Remdesivir) or Adjunctive Therapy Use (e.g., Tocilizumab) | 30 of 30 | 30 of 46 | 76 | NCT04335123 | Trial comparisons |
| Open Label Losartan vs External Controls: Number of Participants With Treatment-related Adverse Events as Assessed by Protocol Definition of AE | 24 of 30 | 44 of 46 | 76 | NCT04335123 | Trial comparisons |
| Open Label Losartan vs External Controls: in Hospital Mortality Rate | 1 of 30 | 3 of 46 | 76 | NCT04335123 | Trial comparisons |
| Open Label Losartan vs External Controls: Number of Participants With Mechanical Ventilation Use | 2 of 30 | 9 of 46 | 76 | NCT04335123 | Trial comparisons |
| Open Label Losartan vs External Controls: Number of Participants With Non-invasive Positive Pressure Ventilation or Heated High Flow Nasal Cannula Use | 6 of 30 | 3 of 46 | 76 | NCT04335123 | Trial comparisons |
| Open Label Losartan vs External Controls: Number of Participants With Extracorporeal Membrane Oxygenation Use | 0 of 30 | 0 of 46 | 76 | NCT04335123 | Trial comparisons |
| Open Label Losartan vs External Controls: Number of Participants With Intolerance to High Dose (50mg) Losartan After Tolerating 25mg | 2 of 30 | 0 of 46 | 76 | NCT04335123 | Trial comparisons |
| Open Label Losartan vs External Controls: deaths from any cause | 1 of 30 | 3 of 46 | 76 | NCT04335123 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021113/comparisons